Lemtrada Forced To Update Black Box Warning To Include Chance of Stroke
RRMS sufferers have little to lose by the time doctors resort to Lemtrada
Friday, May 10, 2019 - The US Food and Drug Administration ordered the maker of anti-seizure drug Lemtrada to warn patients via a "black box" of the stoke hazards caused by taking the drug. The FDA described the warning as follows: "The U.S. Food and Drug Administration (FDA) is warning that rare but serious cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) shortly after they received Lemtrada (alemtuzumab). These problems can lead to permanent disability and even death. As a result, we have added a new warning about these risks to the prescribing information in the drug label and to the patient Medication Guide. We have also added the risk of stroke to the existing Boxed Warning, FDA's most prominent warning."
Black Box warnings are reserved for drugs that may cause serious injury and death. Doctors using Lemtrada are advised to monitor their RRMS patients for the first 24-hours after treatment and to watch for the patient developing headaches, numbness, grogginess, slurred speech, blurred eyesight, and dizziness. Lemtrada is advised as a last resort when all other RRMS drugs have failed. Lemtrada stroke lawsuit attorneys representing families and individuals in the U.S. offer a no obligation, free consultation before filing a claim.
Like cancer or heart disease, multiple sclerosis patients suffer terribly and the disease can take years to play out. Multiple sclerosis is a insidious disease where the outer sheath that protects nerve cells gradually disintegrates allowing the nerve to be continually stimulated. The seizure symptoms of multiple sclerosis usually begin as slight yet uncontrollable tics or mild seizures, occuring at infrequent intervals but gradually increase in frequency and severity until eventually the seizures become continuous. Such a condition is called Relapsing-Remitting Multiple Sclerosis (RRMS). Patients are prescribed a number of different drugs to control their RRMS seizures however most eventually fail to force the doctor to resort to the most toxic and controversial drug on the market, one that is reserved for extreme cases only and only when all other treatments fail. That name of that drug is alemtuzumab, known to many by its trade name, Lemtrada.
Lemtrada is administered by infusion once or twice per year. While Lemtrada has been highly effective at controlling the intervals in between RRMS seizures, the drug's side effects make it of little value. RRMS patients receiving Lemtrada report that within 24-hours of receiving Lemtrada a higher than acceptable number have experienced ischemic and hemorrhagic stroke and cervicocephalic arterial dissection, i.e., a stroke caused by a blood clot that blocks the blood flow to the artery leading to the brain and causing permanent, total or partial paralysis.
According to Multiple Sclerosis News Today, Lemtrada patients commonly experience horrible side effects in addition to the risk of stroke, such as "rashes, joint pain, fungal infections, fatigue, urinary, and upper respiratory tract infections, nausea, viral infections, infusion site infections, thyroid and skin cancer, and lymphoproliferative disorders." On April 12, 2019, Lemtrada was officially put under review by the European Medicines Agency (EMA).
More Recent Lemtrada Stroke Lawsuit News:
- Lemrtrada Risks Were Worth It For One Recent Patient | 4/14/2021
- The Shocking Types of Deaths Caused By Lemtrada | 4/9/2021
- RRMS Has Different Stages With Different Symptoms | 4/5/2021
- Nurses Monitor Lemtrada (Alemtuzumab) Patients For Signs of Its Deadly Side Effects | 3/31/2021
- Lemtrada Can Cause Sudden Death And Many Other Health Issues | 3/8/2021
- Lemtrada May Slow the Progression of Relapse Remitting MS But with Potentially Severe Side Effects | 3/5/2021
- MS Doctors May Need To Be Reminded of Lemtrada's Deadly Side Effects | 3/1/2021
- Doctors Treating RRMS Must Discuss Lemtrada's Deadly Side Effects With Patients | 2/23/2021
- Lemtrada Can Cause An Arterial Dissection and Instant Death | 1/20/2021
- Lemtrada Toxicity May Cause Arterial Dissection Leading To Strokes | 1/13/2021
- People As Young As 20 Should Watch For Symptoms of Multiple Sclerosis | 12/30/2020
- Lemtrada Patients Could Be At Risk When Taking Covid-19 Vaccine | 12/15/2020
- Lemtrada Patients Have May Have Safer Options | 12/8/2020
- Stem Cell Rejection Could Complicate Future RRMS Treatments | 11/25/2020
- Breakthroughs In Stem Cell Transplantation Could Eliminate The Need For Lemtrada And Its Unpredictable Side Effects | 11/19/2020
- Lemtrada Patients Should Know Their Life Is In Danger By Taking Lemtrada | 11/9/2020
- Lemtrada Patients May Try Anything To Keep Multiple Sclerosis In Check | 11/4/2020
- Lemtrada Offers Hope For Those With Advanced RRMS | 10/13/2020
- Lemtrada Sometimes Works Well But Patients Were Only Recently Warned About The Dangers of The Drug | 10/6/2020
- Drugs Like Lemtrada May Benefit MS Patients Right From The Start | 9/29/2020
- Multiple Sclerosis Patients Suffer Fatigue Before Symptoms Gradually Increase | 9/23/2020
- Doctors May Have Dropped Lemtrada Over Covid-19 Fears | 9/2/2020
- Relapse Remitting Multiple Sclerosis Patients May Have a Promising New Drug | 8/25/2020
- Ofatumumab Could Replace Lemtrada For Treatment of Multiple Sclerosis | 8/8/2020
- RRMS Patients Have A Great Source of Information That Can Help Them Deal With Every Aspect of Their Disease | 8/4/2020
- New Information About COVID19 and Taking Lemtrada | 7/16/2020
- The Risks Of Lemtrada Therapy And Other DMTs | 7/9/2020
- Lemtrada Patients Face Possibility Of Living With The After-Effects of a Stroke | 7/6/2020
- A Multiple Sclerosis Doctor Explains The Ins and Outs of Lemtrada for RRMS Patients in a Series of YouTube Videos | 6/22/2020
- Lemtrada Carries Serious Side Effects That Come With The Potential Relief The Drug Offers | 6/1/2020
- Canadians Have One of the World's Highest Rates of Multiple Sclerosis | 5/28/2020
- RRMS Patients Explain Difficulty Managing The Disease During The Covid-19 Pandemic | 5/21/2020
- Relapse Remitting Multiple Sclerosis Patients Share Their Lemtrada Experiences Online | 5/12/2020
- Lemtrada May Also Cause ANCA Vasculitis | 4/27/2020
- Relapse Remitting Multiple Sclerosis Patients (RRMS) Should First Try Telephoning Their Doctors Before Risking Going To The Hospital Directly | 4/22/2020
- Experts Weigh In On Discontinuing Lemtrada Treatments During Pandemic | 4/10/2020
- Lemtrada Patients At Extreme Risk From COVID-19 | 4/8/2020
- Relapse-Remitting Multiple Sclerosis Patients Should Avoid Lemtrada (alemtuzumab) During The Covid-19 Pandemic | 3/20/2020
- Sanofi Forced To Pay $11.8 Million In Alleged Kick-Back Scheme | 3/16/2020
- Newly Diagnosed RRMS Patients Should Avoid Lemtrada and Look to Other Less Toxic Treatments | 3/11/2020
- Lemtrada Deaths Prompt Greater Scrutiny and Harsher Warnings | 2/27/2020
- Lemtrada Patients Dying At An Alarming Rate | 2/10/2020
- Lemtrada Patients Report Positive Experiences From Taking The Anti-MS Drug | 2/4/2020
- Lemtrada Fears May Be Overdone | 1/30/2020
- Some Patients Rave About Lemtrada's Effectiveness While Others Are Left Permanently Disabled | 1/8/2020
- One Last Lemtrada Warning for 2019 | 1/2/2020
- RRMS Patients May Try Stem Cell Therapy if Lemtrada Fails | 12/26/2019
- Lemtrada Patient's Fear of the Unknown Moderated in YouTube Testimonial Videos | 12/16/2019
- Lemtrada Side Effect Awareness Requirements | 12/11/2019
- Lemtrada is serious medication for a serious condition | 11/21/2019
- More Restrictions Placed on Multiple Sclerosis Sufferers Who Wish to Receive Lemtrada Treatment | 11/15/2019
- RRMS Patients May Look To Alternatives To Lemtrada | 11/6/2019
- Europe's Medicine Agency Increases Lemtrada Restrictions | 11/4/2019
- Understand The Pros and Cons of Lemtrada RRMS Treatments | 10/16/2019
- Lemtrada Is More Deadly Than Originally Thought | 10/10/2019
- Obesity Can Make Multiple Sclerosis Medications Less Effective | 10/2/2019
- RRMS Patients Should Consider Lemtrada's Risk of Arterial Dissection | 9/18/2019
- Multiple Sclerosis Patient Have a Difficult Decision To Make When The Disease is in its Latter Stages | 9/6/2019
- Lemtrada's Deadly Side Effects Greater Than Previously Thought | 9/2/2019
- Drug Makers Look to Mitigate Lemtrada's Life-Threatening Side Effects | 8/26/2019
- Lemtrada Relieves RRMS Symptoms Allowing Patients to Enjoy a Better Quality of Life | 8/20/2019
- Lemtrada Causes High Blood Pressure Before a Stroke Occurs | 8/6/2019
- Lemtrada Patients Report Promising Results | 8/1/2019
- The European Medicines Agency is Studying Lemtrada's Side Effects | 7/30/2019
- What To Watch For Indicating You May Have Multiple Sclerosis | 7/10/2019
- Lemtrada May Be Twice as Effective As Its Leading Competitor | 7/5/2019
- Brain Bleeding May Indicate a Lemtrada Stroke is Imminent | 6/27/2019
- Treating Multiple Sclerosis From Many Angles | 6/21/2019
- Lemtrada's Risks Exceed The Black Box Warning | 6/18/2019
- A Long-Term Study Demonstrates Lemtrada's Effectiveness and Adverse Side Effects | 6/11/2019
- A Leading Authority Finds Lemtrada Causes Brain Bleeding | 5/30/2019
- Lemtrada's Incredibly Long List of Adverse Side Effects | 5/23/2019
- The Outlook is Grim For Relapsing-Remitting Multiple Sclerosis (RRMS) Patients | 5/15/2019
- The European Medicines Agency Urges Doctors To Stop Using Lemtrada Effective Immediately | 5/4/2019
- The Pros and Cons of Lemtrada Therapy | 4/19/2019
- Europe's FDA is Reviewing Lemtrada's Stroke Side Effect | 4/15/2019
- Lemtrada is a drug that is approved for patients suffering from relapsing multiple sclerosis but can have serious and often deadly side effects. | 4/9/2019
- MS Doctors Must Weigh The Benefits of Lemtrada Versus The Drug's Stroke Risks | 4/3/2019
- Individuals Suffering From RLMS Now Have a New Drug Called Mavenclad That Can Help Alleviate Seizures | 4/1/2019
- Stroke Warning Added to Lemtrada Boxed Label | 3/28/2019
- Anti MS Drug Lemtrada Carries Multiple Lethal Side Effects | 3/25/2019
No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.